Bedrijfsoverzicht
Mirum Pharmaceuticals, Inc. is a biopharmaceutical entity dedicated to the research, development, and commercialization of innovative therapies designed to treat debilitating rare and orphan diseases. The company operates within the Healthcare sector, specifically in the Biotechnology industry, which implies a focus on high-risk, high-reward scientific innovation rather than traditional manufacturing. This organization employs 369 individuals to support its extensive pipeline of novel treatments, reflecting a mid-sized operational scale for a pre-revenue or early-stage commercial biotech firm. With a market capitalization of $5.74B and annual revenue of $521.31M, the company commands a significant valuation that suggests the market assigns a high premium to its intellectual property and potential future earnings, despite the revenue figure representing only a fraction of its market worth.
Financiële gezondheid
Mirum Pharmaceuticals reported a trailing twelve-month revenue of $521.31M, yet this income resulted in a net loss of $23.36M and an EBITDA of just $2.11M. The substantial gap between the $521.31M revenue and the negative net income reveals a cost structure characterized by high operating expenses, typical of biotechnology firms investing heavily in research, development, and commercialization activities before achieving profitability. Despite the net loss, the company generated a robust free cash flow of $98.56M, indicating strong financial flexibility to fund ongoing operations and R&D without relying on external financing. The gross margin stands at 80.8%, demonstrating the high value of the product relative to the cost of goods sold, while the operating margin of -3.1% and profit margin of -4.5% highlight the ongoing challenges in covering overhead costs and generating net earnings. On the balance sheet, the company holds $383.33M in cash against $319.45M in debt, supported by a debt-to-equity ratio of 101.51%, which suggests a leveraged position where liabilities exceed equity. However, the current ratio of 2.67 indicates a strong short-term liquidity position, ensuring the company can easily meet its immediate financial obligations with its liquid assets. Furthermore, the return on equity of -8.6% and return on assets of -1.8% reveal that management has yet to generate positive returns on the capital invested in the business, reflecting the current stage of the company's life cycle.
Waarderingsbeoordeling
The company currently has a trailing P/E ratio that is not applicable due to negative earnings, while the forward P/E is listed at -876.85, implying that the market is pricing in significant future earnings expectations that have not yet materialized in the current period. The price-to-book ratio of 15.70 indicates that the stock trades at a substantial premium to its book value, a common characteristic for biotechnology companies with valuable intangible assets like patents and clinical data. Alternative valuation metrics such as the price-to-sales ratio of 11.02 and an EV/EBITDA of 2694.80 further underscore that the market values Mirum based on potential growth rather than current profitability or cash flow generation. Regarding price action, the stock has a 52-week high of $109.28 and a 52-week low of $37.83, meaning the current trading price sits within a wide volatility range determined by recent market conditions and investor sentiment. The beta of 0.52 suggests that the stock exhibits lower volatility relative to the broader market, moving less than half as much as the general market index during periods of fluctuation.
Growth & Income
Mirum Pharmaceuticals experienced a year-over-year revenue growth of 49.8%, whereas earnings growth is not applicable due to the company's current lack of net income. The absence of positive earnings growth relative to revenue implies that the company is still in an investment phase where revenue expansion outpaces profit generation, a standard trajectory for biopharmaceutical firms scaling their commercial operations. As a non-dividend payer, the company does not offer a dividend yield or has a payout ratio of 0.0%, indicating that all available earnings are reinvested into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment strategy prioritizes long-term pipeline expansion and market penetration over immediate income generation for investors. The overall profile presents a high-growth, non-income-generating asset that relies on successful product approvals and commercial uptake to eventually transition into a profitable, dividend-paying entity.